Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Tumor Imaging of I-124 PGN65 in Solid Tumors
| Condition | Intervention | Phase |
|---|---|---|
|
Malignant Solid Tumour |
Drug: I-124 PGN650 for PET/CT |
Phase 0 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors |
- To estimate the intensity and distribution in critical and non-critical organs. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
- To estimate the intensity and distribution in critical and non-critical organs. [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
- To estimate the intensity and distribution in critical and non-critical organs. [ Time Frame: Day 3 ] [ Designated as safety issue: No ]
- The presence of tumor imaging using I-124 PGN650 as a PS-targeting agent. [ Time Frame: Day 1, Day 2 and Day 3 ] [ Designated as safety issue: No ]
- Demonstrate the safety of tumor imaging in patients with solid cancers. [ Time Frame: Day 1, Day 2 and Day 3 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 12 |
| Study Start Date: | June 2012 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: I-124 PGN650 for PET/CT |
Drug: I-124 PGN650 for PET/CT
I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
Other Name: I-124 PGN650
|
Detailed Description:
Up to 12 patients (6 men and 6 women) will be enrolled in this open-label, single-arm, tumor imaging and dosimetry study of I-124 PGN650 in solid tumors. All eligible patients who give written, informed consent and meet all inclusion criteria and no exclusion criteria, and whose laboratory results are within specified limits at the screening visit, will be enrolled. All study subjects will receive a single intravenous (IV) dose of I-124 PGN650. Study subjects will have whole body PET/CT imaging at three different timepoints with all patients having PET/CT at 0 to 60 minutes after injection of I-124 PGN650. Study subjects will then be assigned to either a 3 to 5-hour or 6 to 8-hour timepoint and either an 18 to 26 hour or 42 to 52 hour post-injection timepoint. Tumor and whole body radioactivity distribution will be measured.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Signed informed consent form.
- Male or female, ≥ 18 years of age.
- Histologically or cytologically confirmed solid tumors at any stage with at least one lesion (primary, metastatic, or recurrent) ≥ 1.5 cm in diameter documented by CT. If the lesion is located in a lymph node, the shortest diameter of the lymph node must be ≥ 1.5 cm as defined by RECIST 1.1. (Note: See Exclusion Criteria #1.)
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Adequate baseline hematological and organ function, assessed by laboratory values prior to study treatment as follows: absolute neutrophil count (ANC) > 1.0 x 109/L; hemoglobin > 7 g/dL; serum creatinine < 2 x institutional upper limit of normal (IULN); aspartate transaminase (AST) < 2.5 x IULN; alanine transaminase (ALT) < 2.5 x IULN; (if liver metastases are present, ALT and AST < 5 x IULN); total bilirubin < 1.5 x IULN.
- Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence), for the duration of study participation (i.e., from dosing day 1 until study day 8). Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Patient must be willing and able to undergo the imaging studies outlined in the protocol.
Exclusion Criteria
- Only measureable disease (primary or metastatic) is located in or near the thyroid gland, liver, kidney, or urinary bladder.
- Medical conditions such as ischemic heart or lung disease that may be considered an unacceptable risk.
- Females who are lactating or pregnant.
- Persistent acute toxicities from prior anti-cancer therapy.
- History of hypersensitivity to iodine.
- Known bladder outlet obstruction.
- Any condition that would in the Investigator's judgment prevents compliance with the requirements of the protocol.
- Patients with known history of an autoimmune disease- including but not limited to: celiac disease, Crohn's disease, dermatomyositis, Grave's disease, systemic lupus erythematosus, myasthenia gravis, psoriasis, and rheumatoid arthritis.
Contacts and Locations| Contact: Vipin Aggarwal, MD, MPH | (714) 508-6033 | vaggarwal@peregrineinc.com |
| Contact: AJ Leyco | (714) 508-6026 | aleyco@peregrineinc.com |
| United States, Arkansas | |
| University of Arkansas | Not yet recruiting |
| Little Rock, Arkansas, United States, 72205 | |
| Contact: Jim McDonald, MD 501-247-4719 jemcdonald@uams.edu | |
| Contact: Kimberly Morehead (501) 526-7906 moreheadkimberly@uams.edu | |
| Principal Investigator: Jim McDonald, MD | |
| United States, California | |
| City of Hope National Medical Center | Not yet recruiting |
| Duarte, California, United States, 91010 | |
| Contact: Jeff Wong, MD 626-256-4673 jwong@coh.org | |
| Contact: Maria Brooks (626) 256-4673 ext 64402 mbrooks@coh.org | |
| Principal Investigator: Jeff Wong, MD | |
| United States, Maryland | |
| John Hopkins University | Not yet recruiting |
| Baltimore, Maryland, United States, 21287 | |
| Contact: Steve Cho, MD 410-502-7472 scho@jhmi.edu | |
| Contact: Akimosa Jeffrey-Kwanisai (410) 502-1040 ajeffre2@jhmi.edu | |
| Principal Investigator: Steve Cho, MD | |
| United States, Missouri | |
| Washington University School of Medicine, Siteman Cancer Center | Recruiting |
| St. Louis, Missouri, United States, 63110 | |
| Contact: Farrokh Dehdashti, MD 314-362-1474 dehdastif@mir.wustl.edu | |
| Contact: Yongjian Liu 314-362-8431 liuyo@mir.wustl.edu | |
| Principal Investigator: Farrokh Dehdashti, MD | |
More Information
No publications provided
| Responsible Party: | Peregrine Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01632696 History of Changes |
| Other Study ID Numbers: | PPHM 1201 |
| Study First Received: | June 12, 2012 |
| Last Updated: | March 13, 2013 |
| Health Authority: | United States: Institutional Review Board United States: Food and Drug Administration |
Keywords provided by Peregrine Pharmaceuticals:
|
Antibodies, Monoclonal Biologics F(ab')2 Positron-emission tomography (PET) |
Phosphatidylserine (PS) Solid Tumors Tumor Imaging |
Additional relevant MeSH terms:
|
Neoplasms |
ClinicalTrials.gov processed this record on May 22, 2013